In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BioNTech closes $325mm upsized Series B; proceeds amended to $230mm

Executive Summary

BioNTech SE (immunotherapies) raised $325mm through an upsized Series B round, the largest biopharma Series B recorded in Strategic Transactions. Fidelity Management & Research led and was joined by Redmile Group (led the company's $270mm Series A last year), Invus, Mirae Asset Financial Group, Platinum Asset Management, Jebsen Capital, Steam Athena Capital, BVCF Management, and the Struengmann Family Office. Proceeds will fund continued development and manufacturing activities. The company has seven candidates in its pipeline (in eight trials) including a lead neoepitope therapy being developed with partner Genentech that is entering Phase II for metastatic melanoma and in earlier trials for other solid tumors.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Pharmacogenetics-Pharmacogenomics
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies